POET-II Tests Endocarditis Duration
2026-10-08
The POET-II trial puts a stubborn assumption on trial: that more antibiotic days must mean safer care for left-sided infective endocarditis. That equation has long governed treatment of aortic and mitral valve infection, where bacteremia, embolic events, and valvular destruction can turn a small diagnostic delay into catastrophe. The disease offers little mercy. Yet prolonged therapy also carries costs that clinicians cannot dismiss: catheter complications, drug toxicity, disrupted lives, and hospital time that may add burden without adding protection.
The old arithmetic deserves suspicion. POET-II is asking whether duration can be matched more closely to biological risk rather than inherited habit, particularly after patients stabilize and microbiological control is established. This is not an argument for casual shortening. Biofilm biology matters, as do vegetation size, prosthetic material, surgical status, pathogen susceptibility, and the possibility of relapse. The trial's value lies in forcing those variables into a sharper clinical test. A shorter regimen that preserves cure would spare patients exposure; one that permits recurrent infection would reveal the price of false efficiency. At the bedside, the unanswered question remains almost visible: when has the infection truly stopped, and when have clinicians merely grown impatient?
Loading...
